Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (4317)	1/5/1998 6:39:00 PM
From: BigKNY3	Respond to of 23519

Cacaito: <<Have in mind that I am also bias toward good results for Muse, despite trying to be very strict interpreting a study. ( I own VVUS shares ).>> Congratulations on recognizing your own shareholder bias! Every shareholder has a built-in bias in evaluating their company's products and the competition... including myself. Be particularly careful of healthcare professionals who claim their medical backgrounds automatically make them unbiased concerning pharmaceutical products or that they have a greater ability to select pharmaceutical companies to invest in. BigKNY3

To: Cacaito who wrote (4317)	1/5/1998 9:47:00 PM
From: MissLil	Respond to of 23519

I'd be glad to look at the studies. If you have time to find links to the ones that you are most interested in, I'll look at them quickly. FYI: I'm long in VIVUS, think it's a great stock at a bargain basement price. Trying to get my friends and family to buy it. The study with the link posted to it looked good. Much better than the other article. Note that this study was blinded. The study design also allowed for within-subject comparison which sometimes can allow the detection of a benefit in a smaller group of subjects. I can't easily look at the article as the clinical library is across town. However, assuming they did the statistics correctly, this article says that subjects treated with a combination were more likely to achieve intercourse than those treated with either drug alone. This supports the combination therapy which is reportedly being used by urologists. My understanding is that Vivus is working on combination products (but I don't know why I think that or where I heard it.) Prazosin is a drug that has been around for a long time and therefore is probably relatively safe. It has been used for the treatment of hypertension, but is not a common drug for this use at this time. I agree there's a lot of BS (sorry PR) that doesn't mean anything. I suspect from what I've read on the board that Viagra will be a good product also. One doesn't need to decide which is better. However, Muse is likely to have a greater % effect on Vivus' bottom line than Viagra will on Pfizer's.